REFERENCES
1. Baig A M, Khaleeq A, Ali U, et al. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed Neurotropic Mechanisms [J]. ACS Chemical Neuroscience, 2020, 11: 995–998.
2. Plante J A, Liu Y, Liu J, et al. Author Correction: Spike mutation D614G alters SARS-CoV-2 fitness [J]. Nature, 2021, 592: 116–121.
3. Cao Chen, Qi Shi, XiaoPing Dong. SARS-CoV-2 Lambda variant: spatiotemporal distribution and potential [J]. Zoonoses, 2021, 1: 5.
4. Callaway E. Heavily mutated Omicron variant puts scientists on alert [J]. Nature, 2021, 600(7887): 21.
5. Van Doremalen n, BUSHMAKER T, MORRIS DH,et al. Aerosol and surface stability of SARS-Cov-2 as compared with SARS-CoV-1 [J]. N Engl J Med, 2020, 382(16): 1564–1567.
6. HIROSE R, ITOH Y, IKEGAYA H et al. Differences in environmental stability among SARS-CoV-2 variants of concern: both omicron BA.1and BA.2 have higher stability [J]. Clin Microbiol Infect, 2022, 28(11): 1486–1491.
7. Pulliam JRC, Van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa[J]. Science, 2022, 376(6593): eabn4947.
8. Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti–interleukin‐6 receptor antibody in children with systemic‐onset juvenile idiopathic arthritis [J]. Arthritis & Rheumatism, 2005, 52(3): 818–825.
9. Loo Y M, McTamney P M, Arends R H, et al. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans [J]. Science translational medicine, 2022, 14(635): eabl8124.
10. Hammitt L, Dagan R, Yuan Y, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants [J]. New Engl J Med, 2022, 386(9): 837–846.
11. Piechotta V, Iannizzi C, Chai KL et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev, 2021, 5: Cd013600].
12. Jayk Bernal A, Gomes da Silva MM, Musungaie DB et al. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. N Engl J Med, 2021, 386: 509–20.
13. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for highrisk, nonhospitalized adults with covid-19. N Engl J Med, 2022, 386: 1397– 408.
14. Gottlieb RL, Vaca CE, Paredes R et al. Early remdesivir to prevent progression to severe covid-19 in outpatients. N Engl J Med, 2021, 386: 305–315.
15. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—final report. N Engl J Med, 2020, 383: 1813–1826.
16. Chaplin S. Paxlovid: antiviral combination for the treatment of COVID‐19[J]. Prescriber, 2022, 33(3-4): 31–33.
17. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020, 395(10223): 507–513.
18. Hui DSC, Zumla A. Severe acute respiratory syndrome historical, epidemiologic, and clinical features [J]. Infect Dis Clin N Am, 2019,33(4): 869–889.
19. Farouk SS, Fiaccadori E, Cravedi P, et al. COVID-19 and the kidney: what we think we know so far and what we don’t [J]. J Nephrol, 2020, 33(6): 1213–1218.
20. Ao G, Wang Y, Qi X, et al. The association between severe or death COVID-19 and solid organ transplantation: a systematic review and meta-analysis. Transplant Rev (Orlando) 2021(35): 100628.
21. Akalin E, Azzi Y, Bartash R, et al. Covid-19 and kidney transplantation[J]. N Engl J Med, 2020, 382(25): 2475–2477.
22. Columbia University Kidney Transplant Program. Early description of coronavirus 2019 disease in kidney transplant recipients in New York [ J ]. J Am Soc Nephrol, 2020, 31(6): 1150–1156.
23. China approves first homegrown COVID antiviral. [2022-08-01].